Cargando…

Ganghuo Kanggan Decoction in Influenza: Integrating Network Pharmacology and In Vivo Pharmacological Evaluation

Background: Ganghuo Kanggan decoction (GHKGD) is a clinical experience prescription used for the treatment of viral pneumonia in the Lingnan area of China, and its clinical effect is remarkable. However, the mechanism of GHKGD in influenza is still unclear. Objective: To predict the active component...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Yanni, Zhang, Qiong, Long, Haishan, Han, Tiantian, Li, Geng, Zhan, Shaofeng, Li, Yiwei, Li, Zonghui, Jiang, Yong, Liu, Xiaohong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759152/
https://www.ncbi.nlm.nih.gov/pubmed/33362562
http://dx.doi.org/10.3389/fphar.2020.607027
_version_ 1783627071247876096
author Lai, Yanni
Zhang, Qiong
Long, Haishan
Han, Tiantian
Li, Geng
Zhan, Shaofeng
Li, Yiwei
Li, Zonghui
Jiang, Yong
Liu, Xiaohong
author_facet Lai, Yanni
Zhang, Qiong
Long, Haishan
Han, Tiantian
Li, Geng
Zhan, Shaofeng
Li, Yiwei
Li, Zonghui
Jiang, Yong
Liu, Xiaohong
author_sort Lai, Yanni
collection PubMed
description Background: Ganghuo Kanggan decoction (GHKGD) is a clinical experience prescription used for the treatment of viral pneumonia in the Lingnan area of China, and its clinical effect is remarkable. However, the mechanism of GHKGD in influenza is still unclear. Objective: To predict the active components and signaling pathway of GHKGD and to explore its therapeutic mechanism in influenza and to verified it in vivo using network pharmacology. Methods: The potential active components and therapeutic targets of GHKGD in the treatment of influenza were hypothesized through a series of network pharmacological strategies, including compound screening, target prediction and pathway enrichment analysis. Based on the target network and enrichment results, a mouse model of influenza A virus (IAV) infection was established to evaluate the therapeutic effect of GHKGD on influenza and to verify the possible molecular mechanism predicted by network pharmacology. Results: A total of 116 candidate active compounds and 17 potential targets were identified. The results of the potential target enrichment analysis suggested GHKGD may involve the RLR signaling pathway to reduce inflammation in the lungs. In vivo experiments showed that GHKGD had a protective effect on pneumonia caused by IAV-infected mice. Compared with the untreated group, the weight loss in the GHKGD group in the BALB/c mice decreased, and the inflammatory pathological changes in lung tissue were reduced (p < 0.05). The expression of NP protein and the virus titers in lung were significantly decreased (p < 0.05). The protein expression of RIG-I, NF-kB, and STAT1 and the level of MAVS and IRF3/7 mRNA were remarkably inhibited in GHKGD group (p < 0.05). After the treatment with GHKGD, the level of Th1 cytokines (IFN-γ, TNF-α, IL-2) was increased, while the expression of Th2 (IL-5, IL4) cytokines was reduced (p < 0.05). Conclusion: Through a network pharmacology strategy and in vivo experiments, the multi-target and multi-component pharmacological characteristics of GHKGD in the treatment of influenza were revealed, and regulation of the RLR signaling pathway during the anti-influenza process was confirmed. This study provides a theoretical basis for the research and development of new drugs from GHKGD.
format Online
Article
Text
id pubmed-7759152
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77591522020-12-25 Ganghuo Kanggan Decoction in Influenza: Integrating Network Pharmacology and In Vivo Pharmacological Evaluation Lai, Yanni Zhang, Qiong Long, Haishan Han, Tiantian Li, Geng Zhan, Shaofeng Li, Yiwei Li, Zonghui Jiang, Yong Liu, Xiaohong Front Pharmacol Pharmacology Background: Ganghuo Kanggan decoction (GHKGD) is a clinical experience prescription used for the treatment of viral pneumonia in the Lingnan area of China, and its clinical effect is remarkable. However, the mechanism of GHKGD in influenza is still unclear. Objective: To predict the active components and signaling pathway of GHKGD and to explore its therapeutic mechanism in influenza and to verified it in vivo using network pharmacology. Methods: The potential active components and therapeutic targets of GHKGD in the treatment of influenza were hypothesized through a series of network pharmacological strategies, including compound screening, target prediction and pathway enrichment analysis. Based on the target network and enrichment results, a mouse model of influenza A virus (IAV) infection was established to evaluate the therapeutic effect of GHKGD on influenza and to verify the possible molecular mechanism predicted by network pharmacology. Results: A total of 116 candidate active compounds and 17 potential targets were identified. The results of the potential target enrichment analysis suggested GHKGD may involve the RLR signaling pathway to reduce inflammation in the lungs. In vivo experiments showed that GHKGD had a protective effect on pneumonia caused by IAV-infected mice. Compared with the untreated group, the weight loss in the GHKGD group in the BALB/c mice decreased, and the inflammatory pathological changes in lung tissue were reduced (p < 0.05). The expression of NP protein and the virus titers in lung were significantly decreased (p < 0.05). The protein expression of RIG-I, NF-kB, and STAT1 and the level of MAVS and IRF3/7 mRNA were remarkably inhibited in GHKGD group (p < 0.05). After the treatment with GHKGD, the level of Th1 cytokines (IFN-γ, TNF-α, IL-2) was increased, while the expression of Th2 (IL-5, IL4) cytokines was reduced (p < 0.05). Conclusion: Through a network pharmacology strategy and in vivo experiments, the multi-target and multi-component pharmacological characteristics of GHKGD in the treatment of influenza were revealed, and regulation of the RLR signaling pathway during the anti-influenza process was confirmed. This study provides a theoretical basis for the research and development of new drugs from GHKGD. Frontiers Media S.A. 2020-12-10 /pmc/articles/PMC7759152/ /pubmed/33362562 http://dx.doi.org/10.3389/fphar.2020.607027 Text en Copyright © 2020 Lai, Zhang, Long, Han, Li, Zhan, Li, Li, Jiang and Liu http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Lai, Yanni
Zhang, Qiong
Long, Haishan
Han, Tiantian
Li, Geng
Zhan, Shaofeng
Li, Yiwei
Li, Zonghui
Jiang, Yong
Liu, Xiaohong
Ganghuo Kanggan Decoction in Influenza: Integrating Network Pharmacology and In Vivo Pharmacological Evaluation
title Ganghuo Kanggan Decoction in Influenza: Integrating Network Pharmacology and In Vivo Pharmacological Evaluation
title_full Ganghuo Kanggan Decoction in Influenza: Integrating Network Pharmacology and In Vivo Pharmacological Evaluation
title_fullStr Ganghuo Kanggan Decoction in Influenza: Integrating Network Pharmacology and In Vivo Pharmacological Evaluation
title_full_unstemmed Ganghuo Kanggan Decoction in Influenza: Integrating Network Pharmacology and In Vivo Pharmacological Evaluation
title_short Ganghuo Kanggan Decoction in Influenza: Integrating Network Pharmacology and In Vivo Pharmacological Evaluation
title_sort ganghuo kanggan decoction in influenza: integrating network pharmacology and in vivo pharmacological evaluation
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759152/
https://www.ncbi.nlm.nih.gov/pubmed/33362562
http://dx.doi.org/10.3389/fphar.2020.607027
work_keys_str_mv AT laiyanni ganghuokanggandecoctionininfluenzaintegratingnetworkpharmacologyandinvivopharmacologicalevaluation
AT zhangqiong ganghuokanggandecoctionininfluenzaintegratingnetworkpharmacologyandinvivopharmacologicalevaluation
AT longhaishan ganghuokanggandecoctionininfluenzaintegratingnetworkpharmacologyandinvivopharmacologicalevaluation
AT hantiantian ganghuokanggandecoctionininfluenzaintegratingnetworkpharmacologyandinvivopharmacologicalevaluation
AT ligeng ganghuokanggandecoctionininfluenzaintegratingnetworkpharmacologyandinvivopharmacologicalevaluation
AT zhanshaofeng ganghuokanggandecoctionininfluenzaintegratingnetworkpharmacologyandinvivopharmacologicalevaluation
AT liyiwei ganghuokanggandecoctionininfluenzaintegratingnetworkpharmacologyandinvivopharmacologicalevaluation
AT lizonghui ganghuokanggandecoctionininfluenzaintegratingnetworkpharmacologyandinvivopharmacologicalevaluation
AT jiangyong ganghuokanggandecoctionininfluenzaintegratingnetworkpharmacologyandinvivopharmacologicalevaluation
AT liuxiaohong ganghuokanggandecoctionininfluenzaintegratingnetworkpharmacologyandinvivopharmacologicalevaluation